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Abstract
Background: Type 2 helper T-cell cytokines including IL-13 play a central role in the pathogenesis of bronchial
asthma (BA). During the course of our research, our attention was drawn to dipeptidyl peptidase-4 (DPP4) as one of
the molecules that were induced from bronchial epithelial cells (BECs) by IL-13 stimulation. DPP4 could become a
new biomarker or therapeutic target. The aim of this study was to investigate the expression of DPP4 in the
asthmatic airway, and its role in the pathophysiology of asthma.
Methods: BECs were isolated from patients with inhaled corticosteroid-treated asthma (stBA) and inhaled
corticosteroid-naïve asthma (snBA) using bronchoscopy.
DPP4 mRNA expression in freshly isolated BECs and primary cultured BECs with or without IL-13 stimulation was
investigated by microarray analysis and quantitative real-time PCR (qPCR). The distribution of DPP4 protein was
determined by immunostaining of transbronchial lung biopsy specimens from asthma patients. The effect of
recombinant human (rh) DPP4 on the proliferation of lung fibroblasts (HFL-1) and bronchial smooth muscle cells
(BSMCs) was examined, as well as its effect on the production of fibronectin (FN).
Results: DPP4 mRNA was strongly expressed in freshly isolated BECs in snBA, and its expression was significantly
enhanced by IL-13 stimulation. DPP4 mRNA expression in BECs of snBA significantly correlated with exhaled nitric
oxide. Biopsied tissues of the asthmatic airway revealed strong expression of DPP4 protein in BECs from snBA
subjects. rhDPP4 stimulated the proliferation of HFL-1 and BSMCs, and it also enhanced production of FN from
these airway cells.
Conclusion: DPP4 may be involved in the pathologic features of asthmatic airway inflammation and cell
proliferation and FN production.
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Background
Chronic airway inflammation is a major pathologic fea-
ture of bronchial asthma, and type 2 helper T-cell (Th2)
cytokines such as IL-4, IL-5 and IL-13 play important
roles [1]. IL-13 stimulates bronchial epithelial cells
(BECs) and causes the expression of various molecules
involved in eosinophilic airway inflammation. Previously,
we demonstrated that IL-13 induced the production of
nitric oxide (NO) from BECs and acted on lung fibro-
blasts, in coordination with cysteinyl leukotrienes, result-
ing in airway inflammation and remodeling. Therefore,
IL-13 has been widely recognized as playing an import-
ant role in the pathophysiology of asthma [2–5]. Fur-
thermore, IL-13-induced periostin [6] can be measured
in peripheral blood and is used as a companion marker
for predicting the efficacy of anti-IL-13 antibodies in hu-
man asthma patients [7].
Recently, it was shown that DPP4 was induced in nor-
mal human BECs by IL-13 [8]. Another report demon-
strated that the migration of CD4-positive T cells was
decreased in a DPP4 (CD26)-deficient rat model of
asthma [9].
DPP4 is a glycoprotein with a molecular weight of ap-
proximately 110,000, is composed of 766 amino acid res-
idues [10], and is present on the cell membrane and in
the blood as a soluble protein. Van der Velden investi-
gated DPP4 expression in allergic asthma and normal
controls, and showed that DPP4 was mainly expressed
in blood vessels and mucosal glands and T cells [11].
DPP4 acts as a serine protease, which cleaves dipeptides
from peptides containing proline or alanine residues.
DPP4 degrades substrates such as incretin, neuropep-
tides, chemokines and substance P, mostly deactivating
them [12]. DDP4 is also expressed as CD26 on the cell
surface of immune cells. It is known to bind with mole-
cules such as adenosine deaminase (ADA) and regulate
intracellular signaling [13]. Recently, it was reported that
DPP4 induced vascular smooth muscle growth [14], and
it was reported that DPP4 inhibitors suppressed this ac-
tion and contributed to the prevention of myocardial re-
modeling in a rat model [15]. In respiratory research, it
was reported that eosinophilic airway inflammation was
reduced in DPP4-deficient rats [16]. However, the
localization of DPP4 in the airway in non-treated asthma
patients and the direct effects of DPP4 on the patho-
physiology of asthma are not fully understood.
In this study, we used DNA microarray analysis to
comprehensively screen for candidate genes that were
differentially expressed between inhaled corticosteroid-
naïve asthma (snBA) and inhaled corticosteroid (ICS)-
treated asthma (stBA) and showed enhanced expression
in the freshly isolated BECs. We also performed micro-
array analysis using IL-13-stimulated and un-stimulated
primary cultured BECs. Based on the results of these
analyses, our attention became focused on DPP4. There
are numerous reports about genes induced by IL-13
[8, 17, 18], but little information is available on
DPP4. Our attention was drawn to DPP4, which is
expressed in BECs after IL-13 stimulation and DPP4
expression is significantly enhanced in the BECs of
snBA patients. We investigated the correlation be-
tween DPP4 and exhaled nitric oxide (eNO), and ana-
lyzed the localization of DPP4 in BECs, using airway
samples from patients with stBA and snBA. We also
examined the effects of recombinant human (rh)
DPP4 on fibronectin (FN) expression and production




We conducted a retrospective study of 31 asthmatic pa-
tients, comprising 13 with stBA and 18 with snBA, who
visited the Department of Pulmonary Medicine and
Clinical Immunology of Dokkyo University Hospital
from June 2009 to March 2014. For the analysis of the
expression of DPP4 mRNA, bronchial brushings were
performed in these patients (Table 1), including the 7
cases whose cells were used for the microarray analysis
(Table 2). Transbronchial lung biopsy (TBLB) and end-
bronchial biopsy (EBB) were performed in patients
whenever possible.
All subjects met the American Thoracic Society cri-
teria for asthma. Subjects had an FEV1 greater than
80 % of the predicted value and their FEV1/FVC was
greater than 70 %. Subjects with stBA were regularly
treated with inhaled corticosteroid. Subjects with
snBA visiting our hospital for the first time had slight
symptoms such as a continuous cough with wheezing
and nighttime dyspnea, and they had never been
treated with inhaled or oral corticosteroids. Written
informed consent was obtained from participants.
This study was approved by the Ethics Committee of
Dokkyo University School of Medicine (hop-m22095).
Bronchoscopy with bronchial epithelial cell brushing
Bronchial brushings were performed with a standard,
sterile, single-sheathed nylon cytology brush (Olympus
T-260; Olympus, Tokyo, Japan). A total of 4 sets of 10
brushings were performed in the distal airways. The
distal BECs were obtained from the airway situated
Table 1 Characteristics of all subjects of this study
M : F Age %FEV1 FEV1/FVC eNO(ppb) N : E : C
stBA 10 : 3 51 ± 4 88 ± 6 73 ± 4 45 ± 5 3 : 8 : 2
snBA 13 : 5 48 ± 4 83 ± 6 72 ± 3 129 ± 22* 6 : 10 : 2
Data are mean ± SEM. *p < 0.01 vs stBA
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about 1 cm away from the pleura—equivalent to the air-
way of the 10th to 15th branch of Wiebel’s model—with a
diameter of less than 2 mm, which are the so-called
distal airways [19]. The mean cell counts of BECs were
4.4 ± 0.6 × 105 for distal BECs, and 4.9 ± 1.1 × 105 for
proximal BECs, with purity 90 % and viability 80 %, re-
spectively. Whenever possible, biopsies were performed
to obtain samples for immunohistochemistry.
Microarray analysis
Total RNA was extracted from freshly isolated BECs and
primary cultured BECs using Trizol (Invitrogen,
Carlsbad, CA) and the RNeasy Micro kit (QIAGEN,
GmBH, Germany). RNA was quantified by spectrometry
using NanoDrop ND1000, (NanoDrop Technologies,
Wilmington, DE) and the quality of the RNA was
confirmed using an Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA). RNA amplification
products were converted into cDNA. Microarray was
conducted in three of snBA and four of stBA and also
ALI-cultured with or without IL-13 treated BECs (N = 3
respectively). Arrays were scanned in an Agilent Micro-
array Scanner (Agilent Technologies) according to the
manufacturer’s protocol and data were extracted using
Agilent Feature Extraction Software 10.7.3.1 following the
Agilent protocol. Data analysis was carried out by using
GeneSpring GX 12.0 software (Agilent Technologies).
Sample quality control was carried out with GeneSpring®
software and, based on Flag information, unreliable
samples and entities were excluded. In addition, data
was normalized with a percentile shift to the 75 %
percentile, and the errors between experiments were
corrected by aligning the baseline with the median of
all controls. We have presented the 3D PCA score
for microarray analysis performed on freshly isolated
BECs and ALI-cultured BECs. Data is shown in Additional
file 1: Figure S1.
Cell culture
Freshly isolated BECs were seeded into 60 mm tissue-
culture dishes coated with rat-tail type I collagen (BD
Discovery Labware, Bedford, MA). When the BECs
reached 80 % confluence, cells were passaged and seeded
onto collagen-coated polyester 12-well Transwell inserts
with BEBM/DMEM. When the cell layer was 100 %
confluent in the transwells, the culture method was
shifted to the air-liquid interface (ALI) method by re-
moving all of the apical medium. The ALI state was
maintained for 10 days, as previous studies have demon-
strated that this time is required for mucociliary differ-
entiation [2, 20].
Human fetal lung fibroblasts (HFL-1; lung, diploid,
human, passage 3–7 cells) were obtained from the
American Type Culture Collection (Manassas, VA).
Human BSMCs (C-12561; passages 3–7) were ob-
tained from TaKaRa (Shiga, Japan). HFL-1 or BSMCs
were seeded into 24-well tissue culture plates at a
density of 4 × 104 cells/well and were cultured in their
respective conditioned medium until confluence. The
medium was then replaced with 0.5 % FBS conditioned
medium and cells were stimulated with rhDPP4
(Abnova P3467, CA) at a concentration ranging from
0 to 500 ng/ml for 24 to 96 h.
For analysis of cell proliferation, HFL-1 and BSMCs
were seeded into 96-well tissue culture plates at a dens-
ity of 1 × 104 cells/well and were cultured in conditioned
medium until sub-confluence. The cells were then
washed twice and the medium was replaced with serum-
free conditioned medium. After culture for 24 h, this
medium was replaced with conditioned medium con-
taining 0.5 % FBS and the cells were incubated for an-
other 24 h in the presence or absence of various (0 to
500 ng/ml) concentrations of rhDPP4. All cells were
cultured at 37 °C in a 5 % CO2 humidified incubator in
conditioned medium.
Quantitative real-time PCR
The expression of DPP4 mRNA by BECs and the expres-
sion of FN mRNA by HFL-1 and BSMCs were deter-
mined by reverse transcription (RT), followed by real-
time quantitative PCR as described previously [4, 5].
First-strand cDNA was synthesized using the Prime-
Script RT reagent Kit (TaKaRa) with both oligo(dT)
primers and random hexamers.
Reverse transcription was performed with a TaKaRa
PCR Thermal Cycler MP (TP3000). The following are
the sequences of the primers used for amplification of
DPP4, FN and GAPDH:
DPP4: forward primer, GCACGGCAACACATTGAA;
reverse primer, TGAGGTTCTGAAGGCCTAAATC;
FN: forward primer, CTTTGGTGCAGCACAACTTC;
reverse primer, CCTCCTCGAGTCTGAACCAA
GAPDH: forward primer, GCACCGTCAAGGCTGA
GAAC;
reverse primer, TGGTGAAGACGCCAGTGGA.
DNA was amplified for 40 cycles of denaturation
for 5 s at 95 °C and annealing for 30 s at 60 °C,
Table 2 Characteristics of subjects whose cells were analyzed
by DNA microarray
Number Age %FEV1 FEV1/FVC eNO(ppb) N : E : C
stBA 4 47 ± 6 96 ± 6 79 ± 5 58 ± 10 1 : 1: 2
snBA 3 48 ± 4 91 ± 7 72 ± 1 123 ± 25* 1 : 2 : 0
Data are mean ± SEM. *p < 0.05 vs stBA
Definition of abbreviations: N; never smoker, E; ex-smoker, C; current smoker
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using the TaKaRa Thermal Cycler Dice (TP900). The
PCR assays were performed and analyzed using the
Thermal Cycler Dice Real Time System version 4.2
(TaKaRa). The specificity of reactions was determined
by melting curve analysis. The relative expression of
each gene of interest and of GAPDH were calculated
using the ΔΔCt method.
Quantification of DPP4 and fibronectin by ELISA
Cell culture supernatant was collected from ALI cultured
BECs, BSMC and HFL-1 and were stored at -80 °C. DPP4
(R&D Systems, Minneapolis, Minn) or fibronectin
(TakaraBio Inc, Shiga, Japan) were used in standard-
ized sandwich ELISAs, according to the manufac-
turer’s protocol.
Correlations between eNO and DPP4 expression
We also measured eNO before bronchoscopy at a flow
rate of 50 ml/s using the nitric oxide analyzer (NOA)
280i® (Sievers, CO). Correlations between eNO and
DPP4 mRNA expression in distal BECs from asthma
subjects were analyzed.
Immunohistochemistry
Transbronchial lung biopsy specimens from 5 snBA pa-
tients and 5 stBA patients were fixed in formalin. Serial
4-μm sections were immunostained using a rabbit poly-
clonal antibody against DPP4 (1:500) (Abcam, MA). Im-
munohistochemistry was performed using the Dako
EnVisionTM FLEX Mini Kit High pH detection system.
DPP4 expression in the epithelial layer was scored semi-
quantitatively on a scale of 1 to 4 (1 = negative, 2 = weak,
3 =moderate, 4 = strong) by four independent observers,
who were unaware of the sample's identity. The final
scores of DPP4 expression were the mean value of the
four observations and compared between snBA and
stBA.
Cell proliferation stimulated by rhDPP4
HFL-1 and BSMC proliferation was evaluated on the
basis of DNA synthesis that was assessed by measuring
5-bromo-29-deoxyuridine (BrdU) incorporation with an
ELISA kit (Roche), as previously described [5]. This
assay was performed according to the manufacturer’s
instructions.
Statistical analysis
Statistical analysis was performed using the Wilcoxon
rank sum test (Mann–Whitney U test) to compare be-
tween control and each stimulated response. For all
comparisons, P-values < 0.05 were considered significant.
The statistical software used was the JMP version 10
(SAS Institute, Cary, NC).
Results
DNA microarray analysis of BECs from asthma patients
We performed DNA microarray analysis for identifying
differences in gene expression between snBA and stBA.
Table 1 shows the characteristics of subjects in this
study. DPP4 mRNA expression in BECs were analyzed
retrospectively in 31 subjects (stBA, n = 13; snBA, n = 18).
Four of the subjects were current smokers and 18 subjects
had a history of smoking. None of these patients had
COPD; their FEV1/FVC was over 70 % and they had no
low attenuation area on CT. For the snBA patients, the
average eNO level was 128.8 ppb and this value was sig-
nificantly higher than that of stBA patients (44.6 ppb).
Table 2 shows the characteristics of the subjects whose
samples were used for DNA microarray analysis. In the
snBA group, the average age was 49 years old, the average
FEV1/FVC was 72 % and the average eNO level was 123
ppb. In the stBA group, the average age was 47 years old,
the average FEV1/FVC was 78.6 % and the average eNO
level was 58 ppb. All cases were men.
Genes expressed in freshly isolated distal BECs from
snBA and stBA patients in the stable phase were com-
pared using microarray analysis, and 433 genes whose
expression was enhanced greater than 2-fold in snBA
were extracted. In addition, using primary cultured distal
BECs derived from snBA patients (n = 3), which were
cultured using an ALI method, we examined the gene
expression of cells that had been cultured for 10 days in
media with or without IL-13 (10 ng/mL), and extracted
692 genes whose expression was enhanced greater than
2-fold as a result of IL-13 stimulation.
There were 44 genes with greater than 2-fold en-
hanced expressions that were common to both ALI-
cultured and freshly isolated BECs (Fig. 1). The 44 genes
whose expression was induced in these BECs by IL-13
and that had decreased expression as a result of thera-
peutic intervention in asthma patients. Among the
genes, DPP4 attracted our attention. DPP4 was 2.24-fold
increased in snBA compare to stBA of freshly isolated
BECs. Also, DPP4 was increased 6.75-fold increased in
IL-13 treated group of ALI-cultured BECs. DPP4 is a
one the gene that variable in untreated asthma and
IL-13 stimulation.
DPP4 mRNA expression in freshly isolated distal BECs and
correlation with eNO
The expression of DPP4 mRNA measured by qPCR in
freshly isolated BECs obtained from asthma patients by
bronchial brushing was significantly higher in snBA
compared with stBA, in distal airway samples. No sig-
nificant differences in DPP4 mRNA and protein were
found in primary cultures between snBA and stBA pa-
tients (Fig. 2a). Significant correlations were seen be-
tween DPP4 mRNA expression in the distal airways and
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Fig. 1 Results of DNA microarray analysis. In the ALI group, there were 692 genes whose expressions were enhanced more than 2-fold by IL-13
(10 ng/ml) stimulation. In the freshly isolated BEC group, there were 433 genes whose expressions were enhanced more than 2-fold in snBA
samples. The 44 genes common to both groups were extracted from the Venn diagram and displayed together with a heatmap
a b
Fig. 2 DPP4 mRNA expression in freshly isolated BECs from asthma patients by qPCR. DPP4 mRNA was significantly enhanced in distal BECs in
snBA. *P < .05 compared with stBA. b. DPP4 mRNA expression in distal BECs significantly correlated with eNO (r= 0.54, p=0.0377)
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eNO in asthma patients (Fig. 2b: r = 0.54, p = 0.0377).
DPP4 mRNA also showed significant correlation with
iNOS mRNA. This is mentioned in the Discussion and
illustrations are provided in Additional file 2: Figure S2.
DPP4 expression and production induced by IL-13 in
cultured BECs in vitro
Primary cultured BECs isolated from snBA and stBA pa-
tients were cultured by the ALI method and DPP4
mRNA expression and protein production with or with-
out IL-13 stimulation (10 ng/ml) were compared. DPP4
mRNA expression was significantly enhanced with IL-13
stimulation, in BECs from both snBA patients and stBA
patients. DPP4 protein production by measuring by
ELISA was also significantly enhanced by IL-13 stimula-
tion (Fig. 3). There are no significant differences between
snBA and stBA in DPP4 mRNA and protein.
Immunohistochemistry
The distribution of DPP4 protein expression in the distal
airway tissues obtained from asthma patients by biopsy
using bronchoscopy was investigated by immunohisto-
chemistry; representative examples are shown in Fig. 4.
Comparison of samples from asthma patients that were
immunostained with control isotype IgG (Fig. 4a) or
with an anti-DPP4 antibody (Fig. 4b, representative
snBA patient) indicated that the DPP4 protein was
strongly expressed in BECs and in inflammatory cells
such as eosinophils, macrophages and lymphocytes. This
expression was reduced in the representative stBA pa-
tient (Fig. 4c). Figure 4d shows the scores of DPP4
intensity that were determined on a 4-point scale. Com-
parison of the expression of DPP4 in bronchial biopsies
of stBA and snBA patients (N = 5, respectively) revealed
significantly reduced DPP4 intensity in the BECs of stBA
(p < 0.05).We explored whether steroids directly sup-
press DPP4 expression in vitro. DPP4 induced by IL-13
was significantly inhibited by mometasone furoate (MF).
This is shown in Additional file 3: Figure S3. We also in-
vestigated the expression of DPP4 in asthma patients
and non-asthma patients who had undergone surgery
for lung cancer. As expected, the asthma group showed
more staining than the non-asthma group. Representa-
tive photos are shown in Additional file 4: Figure S4.
Proliferation of HFL-1 and BSMCs stimulated by rhDPP4
To investigate the involvement of DPP4 in airway re-
modeling in asthma patients, we examined the prolifera-
tive effect of rhDPP4 on HFL-1 and BSMCs. At 24 h, a
proliferative effect on BSMCs was observed after rhDPP4
stimulation (Fig. 5). The concentration of rhDPP4 that
stimulated the highest growth was 100 ng/ml for BSMCs
and 500 ng/ml for HFL-1.
FN mRNA and protein expression in BSMCs and HFL-1
stimulated by rhDPP4
To examine the direct effect of DPP4, we tested rhDPP4-
induced FN production in BSMCs (Fig. 6a and b) and
HFL-1 (Fig. 6c and d). rhDPP4-stimulated expression of
FN mRNA in BSMCs and HFL-1 was investigated by
qPCR and FN protein concentrations were measured by
ELISA. With regard to FN, rhDPP4 stimulation enhanced
the expression of FN mRNA and FN protein production
in a concentration-dependent manner. The results were






























DPP4 mRNA DPP4 protein
Fig. 3 DPP4 mRNA and protein induced by IL-13 in ALI-cultured BECs. a In primary cultured BECs derived from both snBA and stBA samples,
DPP4 mRNA expression was enhanced by IL-13 (10 ng/ml) stimulation. *P < .001, compared with medium alone. b The production of DPP4 protein
was similarly enhanced by IL-13 (10 ng/ml) stimulation, in cells from both snBA and stBA samples. **P < .01, compared with medium alone
Shiobara et al. Respiratory Research  (2016) 17:28 Page 6 of 11
changes from baseline. We also described actual number
of mean protein concentration in the Fig. 6c and d.
Discussion
There were two main findings in this study. First, DPP4
expressions were enhanced in the BECs of asthma pa-
tients, especially in snBA, and also in BECs stimulated
by IL-13. Second, rhDPP4 stimulates the production of
FN and has proliferative effects on HFL-1 and BSMCs.
With regards to the first finding, we thought that pre-
vious investigations [2–7] of molecules that are involved
in the pathophysiology of asthma through IL-13 stimula-
tion are important not only for the diagnosis of asthma

















Fig. 4 Immunohistochemistry of airway tissue. Distal BECs of snBA samples were stained with a IgG isotype (×200) or b anti-DPP4 antibody.
DPP4 expression can be seen in inflammatory cells, and staining is strongest in the BECs. A sample from a stBA patient after 8 months of
ICS treatment (c). Semi-quantitative analysis of DPP4 intensity scored on a 4-point scale (d). DPP4 protein expression is significantly higher
in snBA (N = 5, respectively). *P < .05, compared with stBA
rhDPP4 (ng/ml)
0 10 50 100 500
* * *
0 10 50 100 500
rhDPP4 (ng/ml)
*        **a b
Fig. 5 Assay of the effect of rhDPP4 on the proliferation of BSMCs and HFL-1 cells. a Proliferative effect of rhDPP4 on BSMCs. Significant proliferation
was seen with rhDPP4 at 50 and 100 ng/ml. But a proliferative effect was not observed at 500 ng/ml. *P < .005 and **P < .05, compared with no
rhDPP4. b In HFL-1, a concentration-dependent proliferative effect was observed at rhDPP4 concentrations of 50 ng/ml and above. *P < .01, compared
with no rhDPP4
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activity and response to treatment. However, the role of
DPP4 in the pathogenesis of asthma is still unclear, and
revealing this role could potentially lead to greater un-
derstanding of the pathophysiology and treatments of
asthma.
In the field of asthma research, one study revealed that
DPP4 mRNA expression was induced by IL-13 stimula-
tion of normal human BECs by microarray analysis [8]
but it did not examined DPP4 in detail. In our study, a
thorough investigation using microarray analysis, qPCR
and ELISA was conducted and we found that DPP4 ex-
pression and production were induced in both BECs
from asthma patients and in cultured BECs stimulated
by IL-13. Significant correlations were seen between
DPP4 mRNA expression in the distal airways and eNO
in asthma patients. Interestingly, DPP4 mRNA expres-
sion is correlated with iNOS mRNA both in distal and
proximal airways. (R = 0.48, p = 0.0176 and R = 0.59, p =
0.0033, respectively.) Data is shown in Additional file 4:
Figure S4.
In an animal model of asthma using DPP4 (CD26)-
deficient rats, it was reported that CD4-positive T-cell
migration decreased even with IL-13 stimulation [9, 21].
In previous studies, it has often been pointed out that
DPP4 is linked to airway inflammation in animal models
of asthma. In our study, snBA patients who underwent
bronchoscopy had a high mean exhaled NO level of 128.8
ppb, which reflects airway inflammation, and stBA pa-
tients undergoing ICS therapy had a relatively low mean
exhaled NO of 44.6 ppb. DPP4 mRNA levels measured
directly using snBA samples were higher than in distal air-
way samples from stBA patients. We also observed by im-
munostaining that DPP4 expression was enhanced in the
airways, especially in BECs in the setting of snBA. These
data suggesting that DPP4 protein expression could de-
crease in these patients following ICS therapy. This is not
inconsistent with the finding of reduction of airway in-
flammation in DPP4-deficient rats [9]. Previously, van
der Velden et al reported that the expression of DPP4
and its enzyme activity were seen not in epithelial cells
mainly but in blood vessels, mucosal glands and T-cells.
They found no difference in DPP4 expression between
allergic asthma and healthy subjects [11]. The discrep-
ancy between their study and ours may be due to the
fact that allergic asthma subjects had not taken oral or





Fig. 6 FN mRNA expression and protein production in BSMCs and HFL-1 stimulated by rhDPP4. a rhDPP4-induced FN mRNA expression in BSMCs
at 72 h. *P < .05 and **P < .001, compared with no rhDPP4. b rhDPP4-induced FN protein production in BSMCs at 96 h. *P < .05, compared with no
rhDPP4. The actual mean concentrations of FN protein (ng/mL) in BSMCs were shown in b as control = 4726.8, DPP4 (10 ng/mL) = 5903.5, DPP4
(50 ng/mL) = 6304.46, DPP4 (100 ng/mL) = 6512.1, and DPP4 (500 ng/mL) = 5903.5. c rhDPP4-induced FN mRNA expression in HFL-1 at 48 h.
*P < .05, compared with no rhDPP4. d. rhDPP4-induced protein production in HFL-1 at 72 h. *P < .05, compared with no rhDPP4. The actual
mean concentrations of FN protein (ng/mL) in HFL-1 were shown in b as control = 26469, DPP4 (50 ng/mL) = 28098, DPP4 (100 ng/mL) = 28777, and
DPP4 (500 ng/mL) = 29737
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study, but our snBA patients had never been treated
with oral or inhaled corticosteroids. The antibody used
in the previous report was a monoclonal antibody,
whereas we used a polyclonal antibody, thus the recog-
nized epitopes and sensitivities could also have been dif-
ferent between the studies. Differences may also exist
between their immunostaining methods and ours. For
example, we used a high-sensitivity visualization system
(Dako EnVision FLEX Mini Kit) because DPP4 stains
well after using this system in our study. Using this sys-
tem may have influenced the results.
Next, we will discuss about the second finding of this
study: cellular proliferation and FN production by
rhDPP4-stimulated BSMCs and HFL-1. It has been pre-
viously reported that DPP4 has three main functions
[22]. The first known function is the immunostimulatory
action of DPP4/CD26, which is primarily expressed on
the surface of lymphocytes. The best known immunosti-
mulatory activity of DPP4 is its contribution to T
lymphocyte activation [23]. T cell activation occurs when
antigen-presenting cells (APC) present antigens using
the major histocompatibility complex to the T-cell
receptor on T lymphocytes. During this process,
caveolin-1 on APC binds with DPP4/CD26 on the sur-
face of T cells, thereby contributing to T-cell activation
through a co-stimulatory effect [24]. The second func-
tion of DPP4 is adhesion on the surface of cells, which is
mediated by collagen and FN. The third function of
DPP4 is its activity as a serine protease. Specifically,
DPP4 is released in a soluble form into the blood
from the surface of cells of various tissues, and acting
as a serine protease, it degrades incretin, gastrointes-
tinal hormones, neuropeptides and chemokines, de-
activating these molecules in many cases [12, 25].
This action leads to the exacerbation of blood glucose
control in diabetes mellitus. Currently, DPP4 inhibi-
tors are being used to treat diabetes mellitus and
it is a useful therapeutic approach. In the field of car-
diology, it has been reported that DPP4 induces vas-
cular smooth muscle growth [26] and that DPP4
inhibitors suppress this action and contribute to the
prevention of myocardial remodeling in mice and hu-
man [15, 27, 28].
Accordingly, we hypothesized that DPP4 would affect
airway remodeling, and we investigated the effects of
DPP4 on BSMCs and HFL-1.
In in vitro experiments, we found that rhDPP4 had a
proliferative effect on HFL-1 and BSMCs (Fig. 5), and
these findings were similar to those of a previous study
reporting that DPP4 had a proliferative effect on vascu-
lar smooth muscle cells [14].
We also found that rhDPP4 induced FN mRNA ex-
pression and protein production in BSMCs and HFL-1
in a concentration-dependent manner (Fig. 6).
The above results suggest that rhDPP4 has a direct
proliferative effect on BSMCs and HFL-1 and induces
the production of extracellular matrix in asthma and
could be involved in airway remodeling.
Currently, the pathways and receptors of DPP4 are un-
clear. However, the fact that DPP4 has properties as a
serine protease suggests that, similar to thrombin, its cell
proliferation and FN production effects might be medi-
ated by receptors such as protease-activated receptor 2
(PAR2) [26] and insulin-like growth factor II receptor
(IGF2R) [29]. Soluble DPP4 directly activates the MAPK
and NF-κB signaling cascade involving PAR2 and result-
ing in the induction of inflammation and proliferation of
human vascular smooth muscle cells [26]. In addition,
DPP-4 dose-dependently increased reactive oxygen spe-
cies (ROS) generation and advanced glycation end prod-
ucts (AGEs) and receptor (RAGE) gene expression in
endothelial cells, which were prevented by anti-IGFR2
antibody blocked the ROS generation in DPP-4-exposed
endothelial cells [29]. These reports suggested that DPP4
act not only as an enzyme, but also activated some re-
ceptors and signal pathways.
This study has some limitations because it was retro-
spective in design. First, the microarray analysis per-
formed in this study could not compare gene expression
between asthma patients and healthy individuals, but ra-
ther, it compared gene expression between snBA and
stBA, and all patients were men. Ideally, a comparison
of gene expression in the BECs of snBA patients and
healthy individuals should be conducted to identify
genes with enhanced expression in asthma. However, it
is difficult to perform bronchoscopies in healthy individ-
uals, which is one of the limitations of our study. Sec-
ond, DPP4 mRNA and protein levels were examined in
a limited number of patients in our study. Bronchosco-
pies performed in asthma patients carry a risk of indu-
cing an attack. As a result, the number of patients
subjected to both microarray analysis and qPCR was
limited.
Future in vitro studies will need to demonstrate
whether DPP4 inhibitors or glucocorticoids prevent FN
expression and production from lung fibroblasts and
bronchial smooth muscle cells. Also, in vivo studies on
the effect of DPP4 or DPP4 inhibitors using animal
models of asthma will be needed. An investigation of the
receptors and signaling pathways involved in IL-13-
mediated enhancement of DPP4 expression should also
be conducted.
Conclusions
We demonstrated that DPP4 is expressed in BECs in hu-
man asthma and is induced by IL-13. Our findings also
suggest that DPP4 is involved in promoting the growth
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of BSMCs and lung fibroblasts, in enhancing the pro-
duction of FN.
Additional files
Additional file 1: 3D PCA score for microarray analyses performed on
freshly isolated BECs and ALI-cultured BECs. The stBA and snBA group
appear similar because one case analyzed before and after treatment was
included; however, overall they seemed to be divisible into two groups.
The control and IL-13 groups were clearly divisible into two groups.
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